#42–Avrum Bluming, M.D. and Carol Tavris, Ph.D.: A compelling case for hormone replacement therapy

Bluming draws the parallel to male testosterone replacement therapy: a study found men on testosterone had higher cardiovascular events at 1 year but lower risk than placebo at 5 years, mirroring the estrogen pattern. The first year of hormone initiation in a vessel-diseased patient is the vulnerable window. For women entering menopause with clean vessels the window risk does not apply. Attia notes that in evaluating women today he would want a zero calcium score and a clean CT angiogram before endorsing HRT in a late-initiating woman.

The early 1970s saw a dramatic drop in HRT prescriptions when a rise in uterine cancer from unopposed estrogen was recognized. By the late 1970s, adding progesterone (cyclic or continuous) had been shown to fully nullify that risk. Progesterone as a breast cancer treatment dates to a randomized trial in the early 1970s where it slightly outperformed tamoxifen.

Bluming frames the hip fracture mortality equivalence as one of the most underappreciated risk-benefit facts in women's health: the disease HRT is feared to possibly cause (breast cancer) kills approximately the same number of women annually as the disease it demonstrably prevents (hip fractures from osteoporosis). Bisphosphonates produce less well-organized bone and carry a long-term fracture side effect not seen with estrogen.

Attia's clinical framing: calcium score zero, CT angiogram clean, lipids normal — then the woman is 'probably okay' to initiate even outside the 10-year window. The first-year risk is real but time-limited. The clinical calculus must weigh ongoing symptom burden, Alzheimer's risk, bone loss rate, and cardiovascular baseline against this first-year hazard.

Bluming's wife was the first patient in his study after two years of progressive cognitive decline, sleep failure, and loss of her passion for reading following chemotherapy-induced menopause. Within two weeks of starting HRT she was restored. The FDA committee member who initially resisted approving Bluming's study asked why he wanted to do the study since 'aren't all your patients going to die anyway.' The study ran for 14 years with no increased cancer outcomes.

Tavris's grapefruit example: 'If I say eating a grapefruit doubles my risk of bunions I need to know what numbers we're talking about. If the numbers jump from one person to two persons out of a hundred or out of a thousand that's trivial.' The WHI absolute risk increase for combination HRT, if real at all, was 9 cases per 10,000 women — which Attia describes as his 'ceiling on risk' when counseling patients.

Bluming cites Barbara Sherwin at McGill as the leading researcher on this question. The mantra that exercise, diet, and mental activity prevent Alzheimer's is unsupported by Bluming — he states flatly that these interventions 'have nothing to do with preventing Alzheimer's disease.' The one potential preventive medication is estrogen.

The WHI control group problem is central: women who had taken hormones before enrollment were randomized to placebo, and these prior-hormone users had a lower-than-expected baseline risk of breast cancer. This artificially inflated the apparent risk ratio in the treatment group. When prior-hormone users are removed from the control group, the increased risk disappears entirely. A 2006 follow-up paper showed the reported risk had vanished with continued follow-up — and made no headlines. By 2017 even principal investigator Joann Manson published that women on hormones had lower breast cancer mortality and lower all-cause mortality than those not on hormones.

Carol Tavris notes that symptoms traditionally listed as 'menopausal' (hot flashes, night sweats) are only the beginning. Joint pains send women to rheumatologists; depression sends them to therapists; cognitive decline is attributed to chemo-brain or stress. Women in their 40s with declining estrogen are misrouted through multiple specialty clinics while the hormonal origin goes unaddressed. Bluming's wife went two years without complaining of night sweats, sleep disruption, joint pains, palpitations, and memory failure before finally raising it — representing a near-complete erasure of her reading capacity — because 'women are supposed to suck that up.'

Bluming ran a 14-year FDA-approved study of HRT in women with a history of successfully treated breast cancer. Across 15 studies in the literature, all but one showed no increased risk of local recurrence, contralateral breast cancer, or distant recurrence among women on hormones versus those not on hormones. The one exception was stopped prematurely after 2.5 years and its own senior author said it 'should not be the last word.' The as-cancer-survivors-live-longer-they-face-heart-disease problem has spawned a new field of cardio-oncology precisely because the 5 million US breast cancer survivors now face a cardiovascular risk that hormonal suppression treatments have elevated.

Bluming walks through the categories of evidence: animal studies showing estrogen protects neuronal survival, lab studies on mechanism, longitudinal observational cohorts, and subgroup analyses from randomized trials. The convergence from these orthogonal study designs is the evidentiary standard Tavris uses as her benchmark for a credible finding. The same evidentiary threshold is never applied in reverse — no convergent data supports the conclusion that estrogen causes Alzheimer's.

The Harvard modeling study by Bayoun and colleagues estimated that if every US woman had taken HRT median female survival would increase by 3.3 years. No other single intervention has such a large projected impact on female longevity. Women typically present with heart disease atypically — nausea rather than crushing chest pain — and are still frequently missed on first presentation.

Women who were especially symptomatic were excluded from the WHI because if they were randomized to placebo they would likely drop out. A 2004 follow-up paper then concluded HRT had 'no benefit on quality of life' — which was true only because women who would benefit most had been systematically excluded. The 13% of women who were symptomatic showed significant improvement but were statistically lost among the 87% who had no symptoms to improve.

For progesterone, Bluming prefers micronized bioidentical progesterone over synthetic progestins (MPA). Progesterone itself has been used to treat breast cancer and in a randomized trial outperformed tamoxifen slightly before being dropped due to fluid retention and nausea. An Indian study showed a single perioperative progesterone injection significantly improved breast cancer prognosis.

Bisphosphonates produce ~6% bone density gain over two years but the bone is less normally organized and atypical subtrochanteric femoral fractures appear in long-term users. Estrogen preserves both density and elasticity indefinitely with no comparable long-term fracture downside.